NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 11th August 2022

**Location:** Zoom

# Committee members present

1. Professor Tom Clutton-Brock [Chair] Present for all items
2. Professor Colin Howie [Vice Chair] Present for all items
3. Ms Dawn Lee Present for all items except #4 (part 2)
4. Professor Dhiraj Tripathi Present for all items
5. Dr Duncan McPherson Present for all items
6. Mr James Tysome Present for all items
7. Dr Jon Bell Present for items #3, 4, 5, 7, 8, 9, and 10
8. Dr Jurjees Hasan Present for all items
9. Mr Kieran Murphy Present for items #3 and 5
10. Mr Mahmoud Elfar Present for all items
11. Mr Marwan Habiba Present for all items
12. Dr Ruchika Gupta Present for all items
13. Mrs Sally Brearley Present for items #3, 4, 5, 6, 7, 8, and 9
14. Dr Stuart Smith Present for all items
15. Professor Tim Jackson Present for all items except #7 (part 2)
16. Ms Veena Soni Present for items #3, 4, and 5 (part 1)

# Committee Apologies:

1. Dr Charlotta Karner
2. Mr Jonathan Anderson
3. Miss Karen Nugent
4. Ms Maria Parsonage
5. Professor Matt Bown
6. Mr Matthew Metcalfe
7. Dr Tim Kinnaird

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Advisor, IPP

Anastasia Chalkidou – Associate Director, IPP

Anna Sparshatt – Senior Editor, Publishing Team

Charlie Campion – Project Manager, IPP

Deonee Stanislaus – Coordinator, IPP

Emma McCarthy – Associate Health Technology Assessment Analyst, IPP

Harriet Edmondson – SPR Public Health, Managed Access

Helen Crosbie – Public Involvement Advisor, Public Involvement Programme

Helen Gallo – Senior Health Technology Assessment Analyst, IPP

John Powell – Consultant Clinical Advisor, IPP

Professor Kevin Harris – Programme Director & Consultant Clinical Advisor, IPP

Lakshmi Mandava – Health Technology Assessment Analyst, IPP

Mark Chapman – Interim Director of Medical Technology, Executive Team

Rosalee Mason – Coordinator, Corporate Office

Sarah Walpole – Clinical Fellow, Quality and Leadership

Suzi McFall – Specialist Registrar, Managed Access

Xia Li – Health Technology Assessment Analyst, IPP

Zoe Jones – Administrator, IPP

# External group representatives present:

Vanessa De Bruin, Clinical Research Director, Medtronic Present for item #4

Heidrun Behrmann, Director of Training and Education, Medtronic Present for item #4

Neil Barman, Chief Scientific Officer, ReCor Medical Present for item #4

Dimitri Augustin, Director of Medical Affairs, ReCor Medical Present for item #4

Marc Oczachowski, CEO, EDAP TMS Present for item #5

Claire Jossan, Head of Clinical Operations, EDAP TMS Present for item #5

Karen Cornett, Vice President, Clinical Operations, Sonablate Present for item #5

Michael A.L. Johnson, M.D, Medical Advisor, Cefaly Present for item #6

Dr Mario de la Torre Estremaroyro, Medical Director, Lumibird Medical Present for item #7

Julien Tixier, Laser Product Manager, Lumibird Medical Present for item #7

Jaime Dickerson, Vice President, Strategic Clinical Evidence, Sightsciences Present for item #8

Rob Hill, Sightsciences Present for item #8

Rik Quaghebeur, Head of Distributor Sales (Europe), Nova-eye Present for item #8

Brock Flowers, Vice President, International Sales, Nova-eye Present for item #8

Kevin Jones, Impact Medical Present for item #9

# Clinical & patient experts present:

Ian Beales, Clinical Associate Professor & Consultant Gastroenterologist, Norfolk and Norwich University Hospital Present for item #3

Dr Sayan Sen, Consultant Cardiologist, Imperial NHS Healthcare Trust Present for item #4

Melvin Lobo, Director Barts BP Clinic & Consultant in CV Medicine, Barts Health NHS Trust Present for item #4

Hashim Ahmed, Professor and Chair of Urology, Imperial College Healthcare NHS Trust Present for item #5

Professor Mark Emberton, Dean UCL Faculty of Medical Sciences, UCL and UCLH NHS Trust Present for item #5

Lizzie Ellis, Policy Officer, Prostate Cancer UK Present for item #5

# Observers present:

Gareth Hopkin, Health Technology Wales Present for items #3 and 4

Matthew Prettyjohns, Health Technology Wales Present for items #3 and 4

Peter Groves, Health Technology Wales Present for items #3 and 4

Susan Myles, Health Technology Wales Present for items #3 and 4

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. None.

1. NNP of IP269/3 Endoluminal gastroplication for gastro-oesophageal reflux disease
	1. Part 1 – Open session
		1. The Chair welcomed the invited clinical experts and members of the public.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced James Tysome, who gave a presentation on the safety and efficacy of Endoluminal gastroplication for gastro-oesophageal reflux disease.
	1. Part 2 – Closed session

Clinical experts and members of the public were asked to leave the meeting: 9:44am.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP923/2 Percutaneous transluminal renal sympathetic denervation for resistant hypertension
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical experts, external group representatives, members of the public and company representatives from Medtronic and ReCor Medical.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* Dawn Lee declared a non-financial professional interest as she has previously quality controlled the UK economic model developed for Medtronic for renal sympathetic denervation for resistant hypertension as part of her work at Lumanity. Her company also continued projects with Medtronic until 2021 and has worked with ReCor, including building a global economic model for ultrasound based renal denervation.
* It was agreed that her declaration would prevent Dawn Lee from participating in part 2 of the discussion for this procedure.
* Kieran Murphy declared a direct financial interest as he is an employee of ReCor Medical Inc.
* It was agreed that his declaration would prevent Kieran Murphy from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Colin Howie, who gave a presentation on the safety and efficacy of Percutaneous transluminal renal sympathetic denervation for resistant hypertension.
	1. Part 2 – Closed session

Company representatives, clinical experts and members of the public were asked to leave the meeting: 11:34am.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP839/2 Focal therapy using high-intensity focused ultrasound for localised prostate cancer
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from EDAP TMS and Sonablate.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Duncan McPherson, who gave a presentation on the safety and efficacy of Focal therapy using high-intensity focused ultrasound for localised prostate cancer.
	1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting: 13:08pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1293/2 Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine
	1. Part 1 – Open session
		1. The chair welcomed the invited external group representatives, members of the public and company representative from Cefaly.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Tim Jackson, who summarised the comments received during the consultation on the draft guidance forTranscutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 14:14pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1860 YAG laser vitreolysis for symptomatic vitreous floaters
	1. Part 1 – Open session
		1. The chair welcomed the invited external group representatives, members of the public and company representatives from Lumibird Medical.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* Tim Jackson declared a financial interest as he performs this procedure in the private sector.
* It was agreed that his declaration would prevent Tim Jackson from participating in part 2 of the discussion for this procedure.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Dhiraj Tripathi, who summarised the comments received during the consultation on the draft guidance for YAG laser vitreolysis for symptomatic vitreous floaters.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 14:37pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1862 Ab interno canaloplasty for open-angle glaucoma
	1. Part 1 – Open session
		1. The chair welcomed the invited external group representatives, members of the public and company representatives from Sightsciences and Nova-eye.
		2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Mahmoud Elfar, who summarised the comments received during the consultation on the draft guidance for Ab interno canaloplasty for open-angle glaucoma.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 15:22pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP148/2 Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder
	1. Part 1 – Open session
		1. The Chair welcomed the invited external group representatives, members of the public and company representatives from Impact Medical.
		2. The Chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then summarised the comments received during the consultation on the draft guidance for Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder.
		2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
	1. Part 2 – Closed session

Company representatives and members of the public were asked to leave the meeting: 15:32pm.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Briefs of IP1929 Percutaneous thrombectomy for pulmonary embolus
	1. Part 1 – Closed session
		1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Jon Bell, who gave a presentation on the safety and efficacy of Percutaneous thrombectomy for pulmonary embolus.
		2. The committee approved the content of the scope as adequate for evaluation of this procedure.
1. Briefs of IP1942 Minimally invasive surgical evacuation of intracerebral haemorrhage using endoscopic assisted clot aspiration
	1. Part 1 – Closed session
		1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Stuart Smith, who gave a presentation on the safety and efficacy of Minimally invasive surgical evacuation of intracerebral haemorrhage using endoscopic assisted clot aspiration.
		2. The committee referred the topic to the NICE Interventional Procedures team for further discussion.
1. Briefs of IP1936 Removal, preservation and subsequent re-implantation of ovarian tissue to restore fertility
	1. Part 1 – Closed session
		1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
	+ 1. The Chair then introduced Marwan Habiba, who gave a presentation on the safety and efficacy of Removal, preservation and subsequent re-implantation of ovarian tissue to restore fertility.
		2. The committee approved the content of the scope as adequate for evaluation of this procedure.
1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 08/09/2022 and will start promptly at 9am.